Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiGOAL
NCT07728097Phase 4Not yet recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 4 trial of cannabidiol in Lennox-Gastaut syndrome (LGS), sponsored by Jazz Pharmaceuticals plc. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT07728097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728097.